Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical allogeneic stem cell transplantation with CD3/CD19-depleted grafts in pediatric high-risk diseases
2006-000393-76Phase 2Terminated
- Sponsor
- Goethe University Frankfurt
- Start
- Apr 2006
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD3/CD19-depleted allogeneic hematopoietic stem cells in hematopoietic malignancies and Hematopathy, sponsored by Goethe University Frankfurt. Primary endpoints: Engraftment rate at day 28 and Onset of engraftment. Started Apr 2006; status: terminated.
02
Drugs
CD3/CD19-depleted allogeneic hematopoietic stem cells
03
Conditions
hematopoietic malignanciesHematopathy
Beyond the preview
Go deeper on 2006-000393-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000393-76.